To evaluate clinical efficacy and safety of autologous serum injection therapy
Not Applicable
Completed
- Conditions
- Diseases of the skin and subcutaneous tissue
- Registration Number
- KCT0001971
- Lead Sponsor
- Ajou University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Current standard medical therapies more than 2 months and moderate-to-severe atopic dermatitis)
2. =10% lesion body surface area (BSA) of atopic dermatitis involvement in area
Exclusion Criteria
Exclusion criteria
1) Patients under the age of 13 year.
2) Patients who are unable to agree on their own (emergency patients, patients with mental disability, patients with limited capacity to consent due to stroke or delirium caused by diabetes).
3) Patients with severe disease whose expected survival duration is less than 3 months.
4) Pregnancy or planned pregnancy within 1 year
5) Skin condition not appropriate for blood sampling and transfusion
6) Presence of skin comorbidities that may interfere with study assessments
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with both a reduction of SCORAD score by = 30% or =50% from baseline.
- Secondary Outcome Measures
Name Time Method Safety verification ;Quality of life measured before and after the treatment ;Blood test parameters (serum immunoglobulin, allergen-specific IgE, IgG autoantibodies, serum eosinophil cationic protein, cytokine, etc)